Generic Liraglutide—Overlooked but Not Forgotten

Gondi S, Kesselheim AS, Rome BN - New England Journal of Medicine

  • Innovation Incentives and Competition
  • Price, Value, and Access

Summary:

The arrival of generic liraglutide offers a lower-cost option for treating diabetes and obesity, which could help expand access and reduce financial strain on health systems grappling with skyrocketing GLP-1 drug spending. Insurers, clinicians, and patients should consider generic liraglutide, noting its proven effectiveness and safety, even though newer GLP-1 medications are more convenient and effective.

VIEW SOURCE

Recent Work from PORTAL

Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Pharmaceutical Industry Pay-Per-Click Advertising Strategies to Influence Public Opinions on Drug Pricing

Eisenkraft Klein D, Kesselheim AS - Clinical Pharmacology & Therapeutics

  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Coverage and Costs for Medications After Medicare Price Negotiation

Cai CL, Bucha S, Kesselheim AS, Rome BN - Journal of General Internal Medicine

  • Price, Value, and Access
Simple graphic of magnifying glass examining papers to signify reviewing research publications.

Methodological Divergence in Oncology HTA: Implications for International Harmonization and the Handling of Uncertainty

Chen NC, Bullement A, Zemplenyi AT, O'Bryant CL, Kaizer AM, Anderson KE, McQueen RB - PharmacoEconomics Open

  • Price, Value, and Access